[Cholinesterase inhibitors in the treatment of mixed dementia]
Abstract:
Mixed dementia is caused by the combination of several simultaneous pathological processes, e.g., Alzheimer's disease and cerebrovascular pathology, Alzheimer's disease and dementia with Lewy bodies, cerebrovascular pathology and dementia with Lewy bodies etc. Many authors consider mixed dementia as the most frequent form of dementia in elderly people. Cholinesterase inhibitors, along with the modulator of glutamate receptors memantine, are commonly used for treatment of different types of dementia, in particular, Alzheimer's disease. Controlled studies have shown their effect in the treatment of dementia with Lewy bodies and vascular dementia. However, there are limited data on the efficacy and safety of the new antidementia drugs in treatment of mixed dementia. In this article, the approaches to the diagnosis of mixed dementia and possibilities of its treatment with cholinesterase inhibitors (donepezil) are described.
Related Concept Videos
Alzheimer's Disease: Treatment
Anticholinesterase Agents: Poisoning and Treatment
Irreversible agents form a strong bond with the cholinesterase enzyme, making it inactive. The breakdown of the phosphorylated enzyme is slower than the...
Indirect-Acting Cholinergic Agonists: Pharmacological Actions
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
Indirect-Acting Cholinergic Agonists: Pharmacokinetics
Reversible agents containing quaternary amines, such as neostigmine and edrophonium, are not easily absorbed orally because they are...
Indirect-Acting Cholinergic Agonists: Mechanism of Action
Reversible inhibitors like edrophonium bind to a specific part of the enzyme called the anionic catalytic site. They form noncovalent bonds, which means they are not strongly attached to the enzyme. This creates a temporary and less stable enzyme–inhibitor complex, leading to...
